Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After The Supply Pact, Will GSK Go For An Equity Deal With Dr. Reddy's?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Weeks after the Paris-headquartered Sanofi-Aventis acquired Hyderabad-based Shantha Biotechnics to galvanize the French drug maker's preventative vaccines manufacturing, analysts are now predicting a deal between Britain's GlaxoSmithKline and Dr. Reddy's - India's second biggest pharmaceutical company as measured by sales
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC072740

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel